» Articles » PMID: 9039093

Region-specific Neuropeptide Y Overflows at Rest and During Sympathetic Activation in Humans

Overview
Journal Hypertension
Date 1997 Jan 1
PMID 9039093
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Neuropeptide Y coexists with norepinephrine in sympathetic nerves and is coreleased into the circulation on sympathetic activation. Little is known about the regional release of neuropeptide Y in humans under normal conditions or in pathophysiological situations of sympathetic activation or denervation. We measured plasma neuropeptide Y-like immunoreactivity and norepinephrine concentrations in samples taken from the brachial artery; coronary sinus; and internal jugular, antecubital, or hepatic veins in volunteers aged 20 to 64 years. Regional neuropeptide Y overflow at rest was calculated from venoarterial plasma concentration differences and plasma flow, and norepinephrine spillover was determined by [3H]norepinephrine infusion techniques. Cardiac release of neuropeptide Y and norepinephrine was examined in response to various stressors as well as in clinical models of sympathetic activation, cardiac failure, and denervation after cardiac transplantation. In healthy volunteers, cardiac, forearm, and jugular venous sample neuropeptide Y concentrations were similar to arterial levels. Hepatic vein plasma neuropeptide Y was greater than arterial both at rest (119 +/- 5% of arterial, n = 7) and after a meal (132 +/- 12%, n = 7), with neuropeptide Y overflows of 6 +/- 2 and 11 +/- 2 pmol/min, respectively. In contrast, hepatomesenteric norepinephrine spillover was not significantly increased by feeding. Although coronary sinus plasma norepinephrine concentrations increased significantly with the cardiac sympathetic activation accompanying mental arithmetic, coffee drinking, isotonic exercise, and bicycle exercise, only the latter powerful sympathetic stimulus increased neuropeptide Y overflow. Cardiac failure was associated with increased resting release of both norepinephrine and neuropeptide Y from the heart, whereas postcardiac transplant norepinephrine spillover from the heart was reduced. The net overflow of neuropeptide Y to plasma observed at rest across the hepatic circulation, but not the cardiac, forearm, or cerebral circulations, indicates that the gut, the liver, or both make a major contribution to systemic plasma neuropeptide Y levels in humans. Sympathetic activation by exercise produced a modest increase in cardiac neuropeptide Y overflow but to only approximately 25% of the resting input from the gut and without a change in arterial neuropeptide Y concentration. Plasma neuropeptide Y measurements are less sensitive than those of plasma norepinephrine concentrations as an index for quantifying sympathetic neural responses regulating the systemic circulation.

Citing Articles

Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes.

Zohora F, Nazari M, Sinusas A Curr Cardiol Rep. 2025; 27(1):61.

PMID: 40009333 DOI: 10.1007/s11886-025-02197-9.


Neuropeptide-Y Levels in ST-Segment-Elevation Myocardial Infarction: Relationship With Coronary Microvascular Function, Heart Failure, and Mortality.

Gibbs T, Tapoulal N, Shanmuganathan M, Burrage M, Borlotti A, Banning A J Am Heart Assoc. 2022; 11(13):e024850.

PMID: 35766271 PMC: 9333365. DOI: 10.1161/JAHA.121.024850.


Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges.

Zoccali C, Ortiz A, Blumbyte I, Rudolf S, Beck-Sickinger A, Malyszko J Nephrol Dial Transplant. 2021; 37(Suppl 2):ii14-ii23.

PMID: 34724060 PMC: 8713155. DOI: 10.1093/ndt/gfab284.


Neuropeptide Y and Metabolism Syndrome: An Update on Perspectives of Clinical Therapeutic Intervention Strategies.

Huang Y, Lin X, Lin S Front Cell Dev Biol. 2021; 9:695623.

PMID: 34307371 PMC: 8299562. DOI: 10.3389/fcell.2021.695623.


Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?.

Bencivenga L, Palaia M, Sepe I, Gambino G, Komici K, Cannavo A Cells. 2021; 10(2).

PMID: 33669936 PMC: 7924864. DOI: 10.3390/cells10020457.